Transforming Growth Factor alpha
"Transforming Growth Factor alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An EPIDERMAL GROWTH FACTOR related protein that is found in a variety of tissues including EPITHELIUM, and maternal DECIDUA. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form which binds to the EGF RECEPTOR.
| Descriptor ID |
D016211
|
| MeSH Number(s) |
D12.644.276.382.750 D12.644.276.963.360 D12.776.467.382.750 D12.776.467.960.360 D23.529.382.750 D23.529.960.360
|
| Concept/Terms |
Transforming Growth Factor alpha- Transforming Growth Factor alpha
- TGF-alpha
- TGFalpha
- Epidermal Growth Factor-Related Transforming Growth Factor
- Epidermal Growth Factor Related Transforming Growth Factor
|
Below are MeSH descriptors whose meaning is more general than "Transforming Growth Factor alpha".
Below are MeSH descriptors whose meaning is more specific than "Transforming Growth Factor alpha".
This graph shows the total number of publications written about "Transforming Growth Factor alpha" by people in this website by year, and whether "Transforming Growth Factor alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Transforming Growth Factor alpha" by people in Profiles.
-
Pharmacologic therapy for Peyronie's disease: what should we prescribe? Expert Opin Pharmacother. 2015 Jun; 16(9):1299-311.
-
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
-
Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther. 2007 Apr; 321(1):84-97.
-
The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001 Dec; 115(4):881-94.
-
Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am Surg. 2000 Apr; 66(4):401-5; discussion 405-6.
-
Oxidant-induced intestinal barrier disruption and its prevention by growth factors in a human colonic cell line: role of the microtubule cytoskeleton. Free Radic Biol Med. 2000 Mar 01; 28(5):727-38.